{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:29:12Z","timestamp":1789770552011,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.psychres.2021.114030","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T12:45:23Z","timestamp":1622119523000},"page":"114030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil"],"prefix":"10.1016","volume":"302","author":[{"given":"Deanna L.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilda","family":"Bidollari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangchun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2021.114030_bib0001","unstructured":"Aristada [package insert]. (2020). Waltham, MA: Alkermes, Inc."},{"key":"10.1016\/j.psychres.2021.114030_bib0002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hup.924","article-title":"Sexual dysfunction in schizophrenia: focus on recent evidence","volume":"23","author":"Baggaley","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114030_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0447.2008.01310.x","article-title":"Side-effects of antipsychotic medication and health-related quality of life in schizophrenia","volume":"119","author":"Bebbington","year":"2009","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.psychres.2021.114030_bib0004","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.psychres.2021.114030_bib0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000447034","article-title":"The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.psychres.2021.114030_bib0006","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/schbul\/sbv001","article-title":"The facts about sexual (dys)function in schizophrenia: an overview of clinically relevant findings","volume":"41","author":"de Boer","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2021.114030_bib0007","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"Dibonaventura","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2021.114030_bib0008","first-page":"74","article-title":"Effect of adjunctive aripiprazole on sexual dysfunction in schizophrenia: a preliminary open-label study","volume":"50","author":"Fujioi","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2021.114030_bib0009","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2021.114030_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/686924","article-title":"Sexual dysfunction and hyperprolactinemia in male psychotic inpatients: a cross-sectional study","volume":"2011","author":"Johnsen","year":"2011","journal-title":"Adv. Urol."},{"key":"10.1016\/j.psychres.2021.114030_bib0011","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2021.114030_bib0012","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/JCP.0000000000000898","article-title":"Adjunct aripiprazole reduces prolactin and prolactin-related adverse effects in premenopausal women with psychosis: results from the DAAMSEL clinical trial","volume":"38","author":"Kelly","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl 2","key":"10.1016\/j.psychres.2021.114030_bib0013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psychres.2021.114030_bib0014","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/wps.20632","article-title":"Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons","volume":"18","author":"Kishimoto","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2021.114030_bib0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-0033-1347177","article-title":"Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics","volume":"46","author":"La Torre","year":"2013","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 44","key":"10.1016\/j.psychres.2021.114030_bib0016","first-page":"5","article-title":"Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat)","volume":"55","author":"Lindstrom","year":"2001","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114030_bib0017","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","article-title":"Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole","volume":"32","author":"Lu","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114030_bib0018","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","article-title":"Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients","volume":"66","author":"Melkersson","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114030_bib0019","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.schres.2019.01.038","article-title":"Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: a 6-month, prospective, open-label study","volume":"208","author":"Miller","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2021.114030_bib0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0269881107082901","article-title":"Change in sexual dysfunction with aripiprazole: a switching or add-on study","volume":"22","author":"Mir","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114030_bib0021","first-page":"1","article-title":"Hyperprolactinaemia - a problem in patients from the reproductive period to the menopause","volume":"16","author":"Palubska","year":"2017","journal-title":"Menopause Rev."},{"key":"10.1016\/j.psychres.2021.114030_bib0022","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psychres.2021.114030_bib0023","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/vhrm.2006.2.4.447","article-title":"Sexual function in hypertensive patients receiving treatment","volume":"2","author":"Reffelmann","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.psychres.2021.114030_bib0024","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s13679-018-0319-6","article-title":"Obesity and sexual functioning","volume":"7","author":"Sarwer","year":"2018","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.psychres.2021.114030_bib0025","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1089\/jwh.2010.2151","article-title":"Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen","volume":"20","author":"Simon","year":"2011","journal-title":"J. Womens Health (2002)"},{"key":"10.1016\/j.psychres.2021.114030_bib0026","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pnpbp.2013.05.010","article-title":"Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data","volume":"45","author":"Tsuboi","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114030_bib0027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114030_bib0028","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1532-5415.1983.tb05123.x","article-title":"The correlation of increased serum prolactin levels with decreased sexual desire and activity in elderly men","volume":"31","author":"Weizman","year":"1983","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.psychres.2021.114030_bib0029","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178121003279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178121003279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:48:32Z","timestamp":1759038512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178121003279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":29,"alternative-id":["S0165178121003279"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2021.114030","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2021.114030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114030"}}